相关产品推荐更多 >

TP1 抗体-TP1 Antibody
¥22
MEF2B 抗体-MEF2B Antibody
¥22
Histo-Blood Group ABO System Transferase (ABO) Antibody (Biotin)/Histo-Blood Group ABO System Transferase (ABO) Antibody (Biotin)/Histo-Blood Group ABO System Transferase (ABO) Antibody (Biotin)
询价
BAI1纯化的MaxPab小鼠源多克隆抗体(B01P) | BAI1 purified MaxPab mouse polyclonal antibody (B01P)
询价
Hypoxia Inducible Factor 1 Alpha Subunit Inhibitor (HIF1AN) Antibody/Hypoxia Inducible Factor 1 Alpha Subunit Inhibitor (HIF1AN) Antibody/Hypoxia Inducible Factor 1 Alpha Subunit Inhibitor (HIF1AN) Antibody
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
FUSIP1
- 亚型:
Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody
- 形态:
Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody
- 保存条件:
建议收到产品后,储存温度为-20°C。避免重复冻融
- 克隆性:
见产品详情页面
- 标记物:
无
- 适应物种:
人
- 保质期:
根据订购时间与产品批次判定,欢迎联系艾美捷咨询确认
- 抗原来源:
重组蛋白
- 目录编号:
abx029516
- 级别:
见产品详情页面
- 库存:
见产品详情页面
- 供应商:
艾美捷
- 宿主:
兔
- 应用范围:
WB
- 浓度:
关于浓度,请联系艾美捷客服确认
- 靶点:
FUSIP1
- 抗体英文名:
Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody
- 抗体名:
FUSIP1
- 规格:
80ul///400ul
产品名称:Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody-Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody
产品货号:abx029516 产品规格:80ul#400ul 应用类型:WB
保存建议:Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody-Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody建议收到产品后,储存温度为-20°C。避免重复冻融
背景资料:This gene product is a member of the serine-arginine (SR) family of proteins, which is involved in constitutive and regulated RNA splicing. Members of this family are characterized by N-terminal RNP1 and RNP2 motifs, which are required for binding to RNA, and multiple C-terminal SR/RS repeats, which are important in mediating association with other cellular proteins. This protein can influence splice site selection of adenovirus E1A pre-mRNA. It interacts with the oncoprotein TLS, and abrogates the influence of TLS on E1A pre-mRNA splicing. This gene has multiple pseudogenes. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. In addition, transcript variants utilizing alternative polyA sites exist.
点击:Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody-Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody查看更详细产品说明,更多应用、储存、价格、货期等信息请致电400-6800-868垂询Abbexa中国区域授权总代理艾美捷科技有限公司。更多特色试剂盒、特色抗体以及特色试剂等产品评论,请点击查看艾美捷特色产品网站。
Abbexa总部位于英国剑桥的剑桥科学园,是一家专业的全球抗体供应商和蛋白质供应商,致力于为生命科学、药物开发和生物技术领域的科学家和研究者提供最佳的客户体验和高质量的产品。产品涵盖一抗、二抗、蛋白质、ELISA试剂盒、酶以及其他用于研究的试剂盒和工具。无论您是进行学术研究,药物开发,疾病研究还是其它生物学研究,Abbexa的单克隆抗体,多克隆抗体,蛋白质和生物试剂均旨在促进您的研究。如果很难找到合适的抗体来满足您的需求,Abbexa还提供了定制蛋白质,肽和抗体的生产渠道。
艾美捷科技与国内外优秀的生物试剂供应商优保持着密切的合作关系,目前已成为众多国际知名品牌的中国总代理或一级代理,主要包括:AmyJet、AAT Bioquest、Abbexa、Abnova、Agrisera、Anogen、Biosensis、Biovision、Caisson Labs、Cayman Chemical、Cell Biolabs、Cytoskeleton、Demeditec、Duchefa、Epigentek、Equitech-Bio、EXBio、Fitzgerald、GeneCopoeia、Hycult Biotech、ImmunoReagents、ImmunoStep、Jackson、LifeSensors、LigaTrap、Mabtech、Matreya、Norgen Biotek、Origene、ProImmune、ProSpec、ScyTek、Solis BioDyne、SouthernBiotech、StressMarq、SySy、US Biological、TRC等,可以在短时间内为用户提供专业的前沿资讯、完备的产品及物流服务。
关键词:Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody,Serine/arginine-Rich Splicing Factor 10 (FUSIP1) Antibody,待更新
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Factor Xa Cleavage of MBP-Fusion protein
after Arg, while hydrophobic residue is not recommended. Excess factor Xa may result in unwanted proteolysis at secondary sites. Avoid the presence of serine-protease inhibitors (like PMSF) during reaction. Theoretically, cleavage must be complete
[资源] 所有的看家基因(housekeeping genes)列表+引物设计服务
_004889 Homo sapiens ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f, isoform 2 (ATP5J2), mRNA 1513 NM_003769 Homo sapiens splicing factor, arginine/serine-rich 9 (SFRS9), mRNA 1207 NM_003910 Homo sapiens maternal G10 transcript
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
技术资料暂无技术资料 索取技术资料




